{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "MANE", "name": "Veradermics, Incorporated", "url": "https://frontierpicks.com/dossiers/MANE/", "json_url": "https://frontierpicks.com/dossiers/MANE.json", "status": "WATCHLIST", "current_conviction": "MEDIUM", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Veradermics’ oral minoxidil story depends on Study ‘304’ replicating the reported hair-growth benefit by year-end 2026. Failed replication, a weekly close below $85, or the reporting window expiring without results would invalidate the case.", "invalidation_trigger": "A weekly close below $85 ends the market thesis; failed placebo-controlled efficacy, treatment-related serious adverse events, or 2026-12-31 passing without Study ‘304’ topline results also invalidate the case.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "precision-biotech-therapeutics", "binary-catalyst-biotech" ], "tags": [], "sources": [], "notes": [ "Clinical-stage: no approved product and no product revenue; every valuation input is a probability-weighted VDPHL01 outcome.", "Listed 2026-02-04 at a $17.00 IPO price — under eight months of trading history, so long-horizon technical structure does not exist yet.", "VDPHL01 competes against off-label generic oral minoxidil already dispensed cheaply through telehealth channels.", "Company guides cash into 2030 from $819.9M held on 2026-06-30; any raise before the '304' readout would contradict that guidance." ], "body_markdown": "## Current Thesis\n\nVeradermics’ extended-release oral minoxidil thesis depends on Study ‘304’ confirming the hair-growth benefit reported in Study ‘302’; failed replication, a weekly close below $85, or missing the guided year-end reporting window would break the case. The company’s 2026-08-11 release still placed the confirmatory results in the second half of 2026. [Company update](https://ir.veradermics.com/news-releases/news-release-details/veradermics-reports-second-quarter-2026-financial-results-and)\n\nThe narrative is maturing — an inference supported by the passage of the conference dates announced for 2026-09-08, 2026-09-09 and 2026-09-10, while the 2026-09-11 reference close remained below the April offering price. As checked on 2026-09-13, the investor-relations homepage still listed the 2026-09-03 conference announcement as its latest release and displayed no upcoming events. That establishes an absence of a newly listed catalyst, not what management said during the presentations. [Conference announcement](https://ir.veradermics.com/news-releases/news-release-details/veradermics-present-upcoming-september-investor-conferences), [Investor relations](https://ir.veradermics.com/)\n\n## Bull Case\n\n- **Controlled efficacy supports the replication case.** The company’s 2026-04-27 Study ‘302’ release reported six-month increases in non-vellus target-area hair count of 30.3 hairs/cm² with once-daily treatment and 33.0 hairs/cm² with twice-daily treatment, versus 7.3 hairs/cm² with placebo; both comparisons had p<0.0001. These are reported trial results, not evidence that Study ‘304’ has succeeded.\n- **Patient reports accompanied measured growth.** In the same 2026-04-27 release, 62.9% of twice-daily participants reported improved or much-improved hair coverage, versus 13.4% with placebo. The company also reported no treatment-related serious adverse events; that observation does not establish safety beyond the reported follow-up.\n- **Reported liquidity covers the development plan.** Cash, cash equivalents and marketable securities totaled $819.9 million on 2026-06-30. Management’s 2026-08-11 projection extended funding into 2030; a subsequent reduction in that forecast would weaken this financing argument. [Quarterly release](https://ir.veradermics.com/news-releases/news-release-details/veradermics-reports-second-quarter-2026-financial-results-and)\n\n## Bear Case\n\n- **The offering price remains unrecovered.** Veradermics priced its public offering at $100.00 per share on 2026-04-29, according to its pricing release. The adjusted reference close on 2026-09-11 was $98.97. This documents issuance followed by a lower market close; it does not identify subsequent sellers.\n- **Analyst optimism preceded confirmation.** The dated StockAnalysis consensus snapshot on 2026-09-04 showed seven covering analysts and an average twelve-month target of $163.50. That is evidence of established analyst attention, not a current positioning measure or proof that all favorable outcomes are priced in.\n- **The principal evidence remains unreplicated.** The 2026-08-11 company update described Study ‘304’ results as forthcoming. Failure to demonstrate statistically significant benefit versus placebo, or disclosure of treatment-related serious adverse events, would undermine the replication thesis. [Company update](https://ir.veradermics.com/news-releases/news-release-details/veradermics-reports-second-quarter-2026-financial-results-and)\n\n## Setup & Price Structure\n\nThe 2026-09-11 adjusted reference close was $98.97, with a three-month price change of 3.0% and a 14-period relative strength index (RSI) of 43.4. The market remained below the $100.00 public-offering reference established on 2026-04-29. These observations do not establish a completed base or expanding participation.\n\nThe research invalidation remains a weekly close below $85, retaining the condition published on 2026-09-05. This is a stated thesis threshold; the supplied observations do not establish $85 as a tested support shelf. Moving-average values, trading-volume history, short interest and current ownership flows are missing, so neither extension above a rising average nor a crowded ownership structure can be measured.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-14 through 2026-10-13:** No confirmed company event was identified for this window on the investor-relations homepage checked on 2026-09-13. The September conference dates have elapsed and are no longer upcoming catalysts. [Investor relations](https://ir.veradermics.com/)\n- **2026-12-31 — reporting-window endpoint:** Management’s 2026-08-11 guidance placed Study ‘304’ topline results and twelve-month Study ‘302’ data in the second half of 2026. This date marks the end of that window, not an announced release appointment; Study ‘304’ is the event on which the replication thesis turns. [Company guidance](https://ir.veradermics.com/news-releases/news-release-details/veradermics-reports-second-quarter-2026-financial-results-and)\n\n## What Would Change Our Mind\n\nFailure to reproduce the placebo-controlled benefit reported on 2026-04-27 would remove the clinical foundation. The market condition is a weekly close below $85; the timing condition is 2026-12-31 passing without Study ‘304’ topline results. A treatment-related serious adverse-event disclosure would also break the stated case.\n\nThe thesis plays out if Study ‘304’ reports statistically significant benefit versus placebo without treatment-related serious adverse events by 2026-12-31, before the published price condition fires. Positive results would resolve this replication question; they would not themselves establish regulatory approval or commercial demand.\n\n## Correlation Notes\n\nThis remains a single-company clinical setup: the 2026-08-11 update ties the next decisive evidence to Veradermics’ own Study ‘304’. No paired sector-return series or measured correlation is supplied with the 2026-09-11 price observations. The available sample cannot support a claim that a biotechnology-sector move explains MANE’s performance, and no group-momentum thesis is assigned.", "first_seen": "2026-09-03", "last_analyzed": "2026-09-13T11:57:08+00:00", "last_synthesized": "2026-09-13", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }